BRIEF-Grail Says Primary Endpoint Of Statistically Significant Combined Stage III-IV Reduction Was Not Met

Reuters

Feb 20

Feb 19 (Reuters) - Grail Inc GRAL.O:

LANDMARK NHS-GALLERI TRIAL DEMONSTRATES A SUBSTANTIAL REDUCTION IN STAGE IV CANCER DIAGNOSES, INCREASED STAGE I AND II DETECTION OF DEADLY CANCERS, AND FOUR-FOLD HIGHER CANCER DETECTION RATE
GRAIL INC: PRIMARY ENDPOINT OF STATISTICALLY SIGNIFICANT COMBINED STAGE III-IV REDUCTION WAS NOT MET
GRAIL INC: PLANS TO EXTEND TRIAL'S FOLLOW UP PERIOD BY 6-12 MONTHS

Source text: ID:nPn7ylVKDa

Further company coverage: GRAL.O

((Reuters.Briefs@thomsonreuters.com;))

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2612235180"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2612235180\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2612235180?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-20 05:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2612235180","market":"us","top_or_hot":-1,"title":"BRIEF-Grail Says Primary Endpoint Of Statistically Significant Combined Stage III-IV Reduction Was Not Met","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Grail Says Primary Endpoint Of Statistically Significant Combined Stage III-IV Reduction Was Not Met</title></head><body><p><span>Feb 19 (Reuters)</span><span> - </span>Grail Inc <span>GRAL.O</span>:</p><ul><li><p>LANDMARK NHS-GALLERI TRIAL DEMONSTRATES A SUBSTANTIAL REDUCTION IN STAGE IV CANCER DIAGNOSES, INCREASED STAGE I AND II DETECTION OF DEADLY CANCERS, AND FOUR-FOLD HIGHER CANCER DETECTION RATE</p></li><li><p>GRAIL INC: PRIMARY ENDPOINT OF STATISTICALLY SIGNIFICANT COMBINED STAGE III-IV REDUCTION WAS NOT MET</p></li><li><p>GRAIL INC: PLANS TO EXTEND TRIAL'S FOLLOW UP PERIOD BY 6-12 MONTHS</p></li></ul><p>Source text: <span>ID:nPn7ylVKDa</span></p><p>Further company coverage: <span>GRAL.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Grail Says Primary Endpoint Of Statistically Significant Combined Stage III-IV Reduction Was Not Met</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Grail Says Primary Endpoint Of Statistically Significant Combined Stage III-IV Reduction Was Not Met\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-20 05:36</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Grail Says Primary Endpoint Of Statistically Significant Combined Stage III-IV Reduction Was Not Met</title></head><body><p><span>Feb 19 (Reuters)</span><span> - </span>Grail Inc <span>GRAL.O</span>:</p><ul><li><p>LANDMARK NHS-GALLERI TRIAL DEMONSTRATES A SUBSTANTIAL REDUCTION IN STAGE IV CANCER DIAGNOSES, INCREASED STAGE I AND II DETECTION OF DEADLY CANCERS, AND FOUR-FOLD HIGHER CANCER DETECTION RATE</p></li><li><p>GRAIL INC: PRIMARY ENDPOINT OF STATISTICALLY SIGNIFICANT COMBINED STAGE III-IV REDUCTION WAS NOT MET</p></li><li><p>GRAIL INC: PLANS TO EXTEND TRIAL'S FOLLOW UP PERIOD BY 6-12 MONTHS</p></li></ul><p>Source text: <span>ID:nPn7ylVKDa</span></p><p>Further company coverage: <span>GRAL.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260219:nTUA5XBTPW:1","article_id":"2612235180","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2612235180","pubTimestamp":1771536988,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Grail Says Primary Endpoint Of Statistically Significant Combined Stage III-IV Reduction Was Not MetFeb 19 (Reuters) - Grail Inc GRAL.O:LANDMARK NHS-GALLERI TRIAL DEMONSTRATES A SUBSTANTIAL REDU","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","GRAL":"GRAIL, Inc."},"translate_title":"BRIEF-Grail表示未达到具有统计学意义的III-IV期联合减少的主要终点","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GRAL":0.9},"content_text":"BRIEF-Grail Says Primary Endpoint Of Statistically Significant Combined Stage III-IV Reduction Was Not MetFeb 19 (Reuters) - Grail Inc GRAL.O:LANDMARK NHS-GALLERI TRIAL DEMONSTRATES A SUBSTANTIAL REDUCTION IN STAGE IV CANCER DIAGNOSES, INCREASED STAGE I AND II DETECTION OF DEADLY CANCERS, AND FOUR-FOLD HIGHER CANCER DETECTION RATEGRAIL INC: PRIMARY ENDPOINT OF STATISTICALLY SIGNIFICANT COMBINED STAGE III-IV REDUCTION WAS NOT METGRAIL INC: PLANS TO EXTEND TRIAL'S FOLLOW UP PERIOD BY 6-12 MONTHSSource text: ID:nPn7ylVKDaFurther company coverage: GRAL.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":true,"code":"91000000","status":"200"}}}